Almogran (Almotriptan) belongs to the triptan class of drugs. It is mainly used for the acute treatment of migraine with or without aura in adults, as well as the acute treatment of migraine headaches in adolescents aged 12-17 years.

How to Use Almogran (Almotriptan)

Standard Dosage for Adults

The recommended dose for the acute treatment of migraine attacks in adults is a single oral dose of 6.25 mg to 12.5 mg.

In clinical practice, the 12.5 mg dose shows a trend of better efficacy in adults. However, individual responses to the dose may vary, so individualized dose selection should be made based on the patient's specific conditions.

Administration Time Management

If the headache is relieved but recurs after the patient's first dose, the medication can be administered again 2 hours later.

It should be noted that the efficacy of re-administration has not been confirmed in placebo-controlled trials for patients who do not respond to the initial dose.

To prevent drug abuse, the maximum daily dose should not exceed 25 mg, and the safety of treating more than 4 migraine episodes on average within 30 days has not been established.

Dosage Adjustment of Almogran (Almotriptan)

Patients with Hepatic Impairment

The recommended starting dose for patients with liver damage is 6.25 mg, and the maximum daily dose within 24 hours should not exceed 12.5 mg.

Patients with Renal Impairment

The recommended starting dose for patients with severe renal impairment is 6.25 mg, and the maximum daily dose within 24 hours should not exceed 12.5 mg.

Adjustment for Drug Interactions

When used concomitantly with potent CYP3A4 inhibitors (such as ketoconazole), the recommended single dose of almotriptan is 6.25 mg, with a maximum daily dose of 12.5 mg.

Concurrent use of almotriptan and potent CYP3A4 inhibitors should be avoided in patients with combined hepatic and renal impairment.

Medication for Special Populations of Almogran (Almotriptan)

Elderly Patients

Elderly patients should use almotriptan with caution, usually starting with a low dose of 6.25 mg.

Although pharmacokinetic studies have shown that the clearance rate of almotriptan is lower in elderly volunteers, there is no significant difference in tolerability between young and elderly people.

The recommended dose for elderly patients with normal renal function is the same as that for young adults.

Pregnant Women

Based on animal experimental data, almotriptan may cause fetal harm. Its use during pregnancy requires careful evaluation of potential benefits and risks.

Lactating Women

It is currently unknown whether almotriptan is excreted in human milk. Considering that many drugs are excreted through breast milk, the pros and cons should be weighed when using it during lactation.

Adolescent Patients

The use of almotriptan in adolescent patients aged 12-17 years has been evaluated, and its tolerability is similar to that in adults.